Jazz Pharmaceuticals, Inc. (Nasdaq:JAZZ) is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. Our unwavering commitment to improving patient care is demonstrated every day through unique patient and physician programs and our ongoing collaboration with patients, physicians and advocacy groups. Building collaborative relationships that foster innovation is the key to our success.





Jazz Pharmaceuticals, Inc. (Nasdaq:JAZZ) and Azur Pharma Limited announced that the companies have agreed to combine in an all-stock transaction that creates a specialty pharmaceutical company incorporated in Ireland with a diversified portfolio of products currently marketed in the United States (US). The combined company would be named Jazz Pharmaceuticals plc.

Azur Pharma is a privately-held, profitable specialty pharmaceutical company headquartered in Dublin, Ireland with US operations in Philadelphia. The company markets ten specialty pharmaceutical products in the US in the central nervous system (CNS) and women's health areas, with expected 2011 net sales of approximately $95 to $100 million.

The combined company is expected to have a diversified revenue base from 12 products currently marketed in the US in the CNS and women's health areas. These include Jazz Pharmaceuticals' currently marketed products, Xyrem® (indicated to treat the two key symptoms of narcolepsy) and Luvox CR® (indicated to treat obsessive compulsive disorder), and the Azur Pharma marketed product portfolio which includes Prialt® (indicated for refractory severe chronic pain), FazaClo® (indicated for treatment resistant schizophrenia), two additional CNS products and a portfolio of women's health products led by Elestrin® (for vasomotor symptoms associated with menopause). The combined company would also have a pipeline of lower-risk development programs including line extensions for the clozapine franchise and certain branded women's health products. Full prescribing information about each product is available on its website.

For further information see www.jazzpharmaceuticals.com.

Read the full article and the disclaimer at: http://drstockpick.com/?p=22098